Copyright Reports & Markets. All rights reserved.

Global Human Gene Therapy Market Growth 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Human Gene Therapy Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for Human Gene Therapy by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for Human Gene Therapy by Country/Region, 2017, 2022 & 2028
  • 2.2 Human Gene Therapy Segment by Type
    • 2.2.1 Non-viral Vectors
    • 2.2.2 Viral Vectors
  • 2.3 Human Gene Therapy Sales by Type
    • 2.3.1 Global Human Gene Therapy Sales Market Share by Type (2017-2022)
    • 2.3.2 Global Human Gene Therapy Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global Human Gene Therapy Sale Price by Type (2017-2022)
  • 2.4 Human Gene Therapy Segment by Application
    • 2.4.1 Neurological Diseases
    • 2.4.2 Cancer
    • 2.4.3 DMD (Duchenne Muscular Dystrophy)
    • 2.4.4 Hepatological Diseases
    • 2.4.5 Others
  • 2.5 Human Gene Therapy Sales by Application
    • 2.5.1 Global Human Gene Therapy Sale Market Share by Application (2017-2022)
    • 2.5.2 Global Human Gene Therapy Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global Human Gene Therapy Sale Price by Application (2017-2022)

3 Global Human Gene Therapy by Company

  • 3.1 Global Human Gene Therapy Breakdown Data by Company
    • 3.1.1 Global Human Gene Therapy Annual Sales by Company (2020-2022)
    • 3.1.2 Global Human Gene Therapy Sales Market Share by Company (2020-2022)
  • 3.2 Global Human Gene Therapy Annual Revenue by Company (2020-2022)
    • 3.2.1 Global Human Gene Therapy Revenue by Company (2020-2022)
    • 3.2.2 Global Human Gene Therapy Revenue Market Share by Company (2020-2022)
  • 3.3 Global Human Gene Therapy Sale Price by Company
  • 3.4 Key Manufacturers Human Gene Therapy Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Human Gene Therapy Product Location Distribution
    • 3.4.2 Players Human Gene Therapy Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Human Gene Therapy by Geographic Region

  • 4.1 World Historic Human Gene Therapy Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global Human Gene Therapy Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global Human Gene Therapy Annual Revenue by Geographic Region
  • 4.2 World Historic Human Gene Therapy Market Size by Country/Region (2017-2022)
    • 4.2.1 Global Human Gene Therapy Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global Human Gene Therapy Annual Revenue by Country/Region
  • 4.3 Americas Human Gene Therapy Sales Growth
  • 4.4 APAC Human Gene Therapy Sales Growth
  • 4.5 Europe Human Gene Therapy Sales Growth
  • 4.6 Middle East & Africa Human Gene Therapy Sales Growth

5 Americas

  • 5.1 Americas Human Gene Therapy Sales by Country
    • 5.1.1 Americas Human Gene Therapy Sales by Country (2017-2022)
    • 5.1.2 Americas Human Gene Therapy Revenue by Country (2017-2022)
  • 5.2 Americas Human Gene Therapy Sales by Type
  • 5.3 Americas Human Gene Therapy Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Human Gene Therapy Sales by Region
    • 6.1.1 APAC Human Gene Therapy Sales by Region (2017-2022)
    • 6.1.2 APAC Human Gene Therapy Revenue by Region (2017-2022)
  • 6.2 APAC Human Gene Therapy Sales by Type
  • 6.3 APAC Human Gene Therapy Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe Human Gene Therapy by Country
    • 7.1.1 Europe Human Gene Therapy Sales by Country (2017-2022)
    • 7.1.2 Europe Human Gene Therapy Revenue by Country (2017-2022)
  • 7.2 Europe Human Gene Therapy Sales by Type
  • 7.3 Europe Human Gene Therapy Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Human Gene Therapy by Country
    • 8.1.1 Middle East & Africa Human Gene Therapy Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa Human Gene Therapy Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa Human Gene Therapy Sales by Type
  • 8.3 Middle East & Africa Human Gene Therapy Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Human Gene Therapy
  • 10.3 Manufacturing Process Analysis of Human Gene Therapy
  • 10.4 Industry Chain Structure of Human Gene Therapy

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 Human Gene Therapy Distributors
  • 11.3 Human Gene Therapy Customer

12 World Forecast Review for Human Gene Therapy by Geographic Region

  • 12.1 Global Human Gene Therapy Market Size Forecast by Region
    • 12.1.1 Global Human Gene Therapy Forecast by Region (2023-2028)
    • 12.1.2 Global Human Gene Therapy Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Human Gene Therapy Forecast by Type
  • 12.7 Global Human Gene Therapy Forecast by Application

13 Key Players Analysis

  • 13.1 Biogen
    • 13.1.1 Biogen Company Information
    • 13.1.2 Biogen Human Gene Therapy Product Offered
    • 13.1.3 Biogen Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 Biogen Main Business Overview
    • 13.1.5 Biogen Latest Developments
  • 13.2 Sarepta Therapeutics
    • 13.2.1 Sarepta Therapeutics Company Information
    • 13.2.2 Sarepta Therapeutics Human Gene Therapy Product Offered
    • 13.2.3 Sarepta Therapeutics Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 Sarepta Therapeutics Main Business Overview
    • 13.2.5 Sarepta Therapeutics Latest Developments
  • 13.3 Gilead Sciences
    • 13.3.1 Gilead Sciences Company Information
    • 13.3.2 Gilead Sciences Human Gene Therapy Product Offered
    • 13.3.3 Gilead Sciences Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 Gilead Sciences Main Business Overview
    • 13.3.5 Gilead Sciences Latest Developments
  • 13.4 Amgen
    • 13.4.1 Amgen Company Information
    • 13.4.2 Amgen Human Gene Therapy Product Offered
    • 13.4.3 Amgen Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 Amgen Main Business Overview
    • 13.4.5 Amgen Latest Developments
  • 13.5 Novartis
    • 13.5.1 Novartis Company Information
    • 13.5.2 Novartis Human Gene Therapy Product Offered
    • 13.5.3 Novartis Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Novartis Main Business Overview
    • 13.5.5 Novartis Latest Developments
  • 13.6 Orchard Therapeutics
    • 13.6.1 Orchard Therapeutics Company Information
    • 13.6.2 Orchard Therapeutics Human Gene Therapy Product Offered
    • 13.6.3 Orchard Therapeutics Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Orchard Therapeutics Main Business Overview
    • 13.6.5 Orchard Therapeutics Latest Developments
  • 13.7 Spark Therapeutics
    • 13.7.1 Spark Therapeutics Company Information
    • 13.7.2 Spark Therapeutics Human Gene Therapy Product Offered
    • 13.7.3 Spark Therapeutics Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Spark Therapeutics Main Business Overview
    • 13.7.5 Spark Therapeutics Latest Developments
  • 13.8 Agc Biologics
    • 13.8.1 Agc Biologics Company Information
    • 13.8.2 Agc Biologics Human Gene Therapy Product Offered
    • 13.8.3 Agc Biologics Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 Agc Biologics Main Business Overview
    • 13.8.5 Agc Biologics Latest Developments
  • 13.9 Anges
    • 13.9.1 Anges Company Information
    • 13.9.2 Anges Human Gene Therapy Product Offered
    • 13.9.3 Anges Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.9.4 Anges Main Business Overview
    • 13.9.5 Anges Latest Developments
  • 13.10 Bluebird Bio
    • 13.10.1 Bluebird Bio Company Information
    • 13.10.2 Bluebird Bio Human Gene Therapy Product Offered
    • 13.10.3 Bluebird Bio Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.10.4 Bluebird Bio Main Business Overview
    • 13.10.5 Bluebird Bio Latest Developments
  • 13.11 Jazz Pharmaceuticals
    • 13.11.1 Jazz Pharmaceuticals Company Information
    • 13.11.2 Jazz Pharmaceuticals Human Gene Therapy Product Offered
    • 13.11.3 Jazz Pharmaceuticals Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.11.4 Jazz Pharmaceuticals Main Business Overview
    • 13.11.5 Jazz Pharmaceuticals Latest Developments
  • 13.12 Dynavax Technologies
    • 13.12.1 Dynavax Technologies Company Information
    • 13.12.2 Dynavax Technologies Human Gene Therapy Product Offered
    • 13.12.3 Dynavax Technologies Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.12.4 Dynavax Technologies Main Business Overview
    • 13.12.5 Dynavax Technologies Latest Developments
  • 13.13 Human Stem Cells Institute
    • 13.13.1 Human Stem Cells Institute Company Information
    • 13.13.2 Human Stem Cells Institute Human Gene Therapy Product Offered
    • 13.13.3 Human Stem Cells Institute Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.13.4 Human Stem Cells Institute Main Business Overview
    • 13.13.5 Human Stem Cells Institute Latest Developments
  • 13.14 Sibiono Genetech
    • 13.14.1 Sibiono Genetech Company Information
    • 13.14.2 Sibiono Genetech Human Gene Therapy Product Offered
    • 13.14.3 Sibiono Genetech Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.14.4 Sibiono Genetech Main Business Overview
    • 13.14.5 Sibiono Genetech Latest Developments
  • 13.15 Shanghai Sunway Biotech
    • 13.15.1 Shanghai Sunway Biotech Company Information
    • 13.15.2 Shanghai Sunway Biotech Human Gene Therapy Product Offered
    • 13.15.3 Shanghai Sunway Biotech Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.15.4 Shanghai Sunway Biotech Main Business Overview
    • 13.15.5 Shanghai Sunway Biotech Latest Developments
  • 13.16 Uniqure N.V.
    • 13.16.1 Uniqure N.V. Company Information
    • 13.16.2 Uniqure N.V. Human Gene Therapy Product Offered
    • 13.16.3 Uniqure N.V. Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.16.4 Uniqure N.V. Main Business Overview
    • 13.16.5 Uniqure N.V. Latest Developments
  • 13.17 Gensight Biologics S.A.
    • 13.17.1 Gensight Biologics S.A. Company Information
    • 13.17.2 Gensight Biologics S.A. Human Gene Therapy Product Offered
    • 13.17.3 Gensight Biologics S.A. Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.17.4 Gensight Biologics S.A. Main Business Overview
    • 13.17.5 Gensight Biologics S.A. Latest Developments
  • 13.18 Celgene Corporation
    • 13.18.1 Celgene Corporation Company Information
    • 13.18.2 Celgene Corporation Human Gene Therapy Product Offered
    • 13.18.3 Celgene Corporation Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.18.4 Celgene Corporation Main Business Overview
    • 13.18.5 Celgene Corporation Latest Developments
  • 13.19 Cellectis
    • 13.19.1 Cellectis Company Information
    • 13.19.2 Cellectis Human Gene Therapy Product Offered
    • 13.19.3 Cellectis Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.19.4 Cellectis Main Business Overview
    • 13.19.5 Cellectis Latest Developments
  • 13.20 Sangamo Therapeutics
    • 13.20.1 Sangamo Therapeutics Company Information
    • 13.20.2 Sangamo Therapeutics Human Gene Therapy Product Offered
    • 13.20.3 Sangamo Therapeutics Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.20.4 Sangamo Therapeutics Main Business Overview
    • 13.20.5 Sangamo Therapeutics Latest Developments
  • 13.21 Mustang Bio
    • 13.21.1 Mustang Bio Company Information
    • 13.21.2 Mustang Bio Human Gene Therapy Product Offered
    • 13.21.3 Mustang Bio Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.21.4 Mustang Bio Main Business Overview
    • 13.21.5 Mustang Bio Latest Developments
  • 13.22 AGTC
    • 13.22.1 AGTC Company Information
    • 13.22.2 AGTC Human Gene Therapy Product Offered
    • 13.22.3 AGTC Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.22.4 AGTC Main Business Overview
    • 13.22.5 AGTC Latest Developments
  • 13.23 Poseida Therapeutics
    • 13.23.1 Poseida Therapeutics Company Information
    • 13.23.2 Poseida Therapeutics Human Gene Therapy Product Offered
    • 13.23.3 Poseida Therapeutics Human Gene Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.23.4 Poseida Therapeutics Main Business Overview
    • 13.23.5 Poseida Therapeutics Latest Developments

14 Research Findings and Conclusion

The global market for Human Gene Therapy is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Human Gene Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Human Gene Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Human Gene Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Human Gene Therapy market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Human Gene Therapy players cover Biogen, Sarepta Therapeutics, Gilead Sciences, Amgen and Novartis, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Human Gene Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Human Gene Therapy market, with both quantitative and qualitative data, to help readers understand how the Human Gene Therapy market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:
The study segments the Human Gene Therapy market and forecasts the market size by Type (Non-viral Vectors and Viral Vectors,), by Application (Neurological Diseases, Cancer, DMD (Duchenne Muscular Dystrophy) and Hepatological Diseases), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Non-viral Vectors
Viral Vectors

Segmentation by application
Neurological Diseases
Cancer
DMD (Duchenne Muscular Dystrophy)
Hepatological Diseases
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Biogen
Sarepta Therapeutics
Gilead Sciences
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Human Stem Cells Institute
Sibiono Genetech
Shanghai Sunway Biotech
Uniqure N.V.
Gensight Biologics S.A.
Celgene Corporation
Cellectis
Sangamo Therapeutics
Mustang Bio
AGTC
Poseida Therapeutics

Chapter Introduction
Chapter 1: Scope of Human Gene Therapy, Research Methodology, etc.
Chapter 2: Executive Summary, global Human Gene Therapy market size (sales and revenue) and CAGR, Human Gene Therapy market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Human Gene Therapy sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Human Gene Therapy sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Human Gene Therapy market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Biogen, Sarepta Therapeutics, Gilead Sciences, Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics and Anges, etc.
Chapter 14: Research Findings and Conclusion

Buy now